Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Presynaptic block

Kerr LM, Yoshikami D. A venom peptide with a novel presynaptic blocking action. Nature 1984 308(5956) 282-4. [Pg.138]

Noradrenaline transporters (NAT) are localized in the presynaptic plasma membrane of adrenergic nerve terminals. They belong to a family of proteins with 12 putative transmembrane proteins which are responsible for recycling of released neurotransmitters (noradrena-line/adrenaline, dopamine, serotonin, amino acid transmitters) back into the presynaptic nerve ending. Noradrenaline transporters can be blocked by a number of different antidepressant drags, including tricyclic antidepressants (e.g. desipramine) and selective noradrenaline reuptake inhibitors (e.g. reboxetine). [Pg.883]

Methylphenidate like cocaine largely acts by blocking reuptake of monoamines into the presynaptic terminal. Methylphenidate administration produces an increase in the steady-state (tonic) levels of monoamines within the synaptic cleft. Thus, DAT inhibitors, such as methylphenidate, increase extracellular levels of monoamines. In contrast, they decrease the concentrations of the monoamine metabolites that depend upon monoamine oxidase (MAO), that is, HVA, but not catecholamine-o-methyltransferase (COMT), because reuptake by the transporter is required for the formation of these metabolites. By stimulating presynaptic autoreceptors, methylphenidate induced increase in dopamine transmission can also reduce monoamine synthesis, inhibit monoamine neuron firing and reduce subsequent phasic dopamine release. [Pg.1039]

Reuptake transporters are structures within the cell membranes of the presynaptic nerve terminal that serve to transport biogenic amines released from vesicles back into the nerve cell. These structures are targets for antidepressants, which block the transporter, thus increasing the bioavailability of neurotransmitters at postsynaptic receptors. [Pg.1079]

Tetanus is a disease caused by the release of neurotoxins from the anaerobic, spore-forming rod Clostridium tetani. The clostridial protein, tetanus toxin, possesses a protease activity which selectively degrades the pre-synaptic vesicle protein synaptobrevin, resulting in a block of glycine and y-aminobutyric acid (GABA) release from presynaptic terminals. Consistent with the loss of neurogenic motor inhibition, symptoms of tetanus include muscular rigidity and hyperreflexia. The clinical course is characterized by increased muscle tone and spasms, which first affect the masseter muscle and the muscles of the throat, neck and shoulders. Death occurs by respiratory failure or heart failure. [Pg.1196]

In the venom of C. geographus and other fish-hunting species, the conotoxins isolated so far can be divided into three major classes (1-4) o -conotoxms which block neuronal calcium channels at the presynaptic terminus of the neuromuscular junction, a-conotoxins which inhibit the acetylcholine receptor at the postsynaptic terminus, and x-conotoxins which block Na channels on the muscle membrane. [Pg.267]

While the amount of noradrenaline released from the terminals can be increased by nerve stimulation, it can be increased much more by drugs, like phenoxybenzamine, which block presynaptic a-adrenoceptors. These receptors are normally activated by increased noradrenaline in the synapse and trigger a feedback cascade, mediated by... [Pg.172]

Increase release. This should follow block of any presynaptic inhibitory autoreceptors. It is not practical at present to increase the vesicular release of a particular NT. [Pg.296]

Figure 20.1 Schematic diagram illustrating how antidepressants increase the concentration of extraneuronal neurotransmitter (noradrenaline and/or 5-HT). In the absence of drug (b), monoamine oxidase on the outer membrane of mitochondria metabolises cytoplasmic neurotransmitter and limits its concentration. Also, transmitter released by exocytosis is sequestered from the extracellular space by the membrane-bound transporters which limit the concentration of extraneuronal transmitter. In the presence of a MAO inhibitor (a), the concentration of cytoplasmic transmitter increases, causing a secondary increase in the vesicular pool of transmitter (illustrated by the increase in the size of the vesicle core). As a consequence, exocytotic release of transmitter is increased. Blocking the inhibitory presynaptic autoreceptors would also increase transmitter release, as shown by the absence of this receptor in the figure. In the presence of a neuronal reuptake inhibitor (c), the membrane-bound transporter is inactivated and the clearance of transmitter from the synapse is diminished... Figure 20.1 Schematic diagram illustrating how antidepressants increase the concentration of extraneuronal neurotransmitter (noradrenaline and/or 5-HT). In the absence of drug (b), monoamine oxidase on the outer membrane of mitochondria metabolises cytoplasmic neurotransmitter and limits its concentration. Also, transmitter released by exocytosis is sequestered from the extracellular space by the membrane-bound transporters which limit the concentration of extraneuronal transmitter. In the presence of a MAO inhibitor (a), the concentration of cytoplasmic transmitter increases, causing a secondary increase in the vesicular pool of transmitter (illustrated by the increase in the size of the vesicle core). As a consequence, exocytotic release of transmitter is increased. Blocking the inhibitory presynaptic autoreceptors would also increase transmitter release, as shown by the absence of this receptor in the figure. In the presence of a neuronal reuptake inhibitor (c), the membrane-bound transporter is inactivated and the clearance of transmitter from the synapse is diminished...
In addition to its relatively high affinity at postsynaptic 5-HT receptors, MDMA exhibited high affinity for 5-HT uptake sites and has been shown to increase the release of [ H]5-HT and block [ H]5-HT uptake in vitro. These data suggest that some of the actions of MDMA may be mediated at presynaptic binding sites. With respect to [ H]5-HT release, MDMA has been reported to increase the release of [ H]5-HT from brain synaptosomes (Nichols et al. 1982) and hippocampal slices (Johnson et al. 1986). With respect to uptake blockade, MDMA has been reported to competitively inhibit H-5-HT uptake in vitro (Shulgin 1986). Furthermore, the neurotoxic effects of in vivo administration of MDMA on serotonin terminals can be blocked by concomitant administration of the 5-HT uptake blocker citalo-pram (Battaglia et al. 1988b Schmidt and Taylor 1987). Additional evidence in support of the hypothesis that MDMA produces some of its... [Pg.251]

Phencyclidine (PCP) Selectively Blocks Certain Presynaptic Potassium Channels... [Pg.50]

Sorensen and Blaustein 1985a). In view of the enhanced neuro-transmitter release that would be expected to accompany block of presynaptic K channels (Llinas et al. 1976), this mechanism could explain the PCP-induced "dopamine storm" (Rappolt et al. 1980). Such altered synaptic transmission at central synapses may underlie the disordered behavior characteristic of PCP intoxication. [Pg.51]

There is ample precedent for a modulatory role of K channels in behavior. The K channel blocker, 4-AP, selectively blocks component T (Bartschat and Blaustein 1985a). prolongs nerve action potentials, and enhances neurotransmitter release (Llinas et al. 1975). In man, intoxication with this agent may lead to dissociative behavior, agitation, confusion, convulsions, and coma (Spyker et al. 1980). However, the behavioral aberrations induced by 4-AP differ qualitatively from those induced by PCP. This implies that block of various types of presynaptic K channels may modify behavior and mental activity however, the precise nature of the behavioral manifestations is likely to depend upon the specific type of K channel that is affected. [Pg.61]

Bartschat, D.K. Sorensen, R.G. and Blaustein, M.P. Psychotomimetic "sigma opiates" and phencyclidines selectively block the same K channels in presynaptic nerve terminals. Soc Neurosci Abst. 11 316a, 1985. [Pg.62]

Selegiline (Eldepryl ) Blocks MAOB metabolism and presynaptic reuptake of DA in the brain Start with 5 mg in the morning if symptoms continue, add 5 mg at noon 5 mg daily may be as clinically effective as 10 mg daily with fewer side effects... [Pg.479]


See other pages where Presynaptic block is mentioned: [Pg.553]    [Pg.336]    [Pg.553]    [Pg.890]    [Pg.553]    [Pg.336]    [Pg.553]    [Pg.890]    [Pg.517]    [Pg.538]    [Pg.237]    [Pg.141]    [Pg.360]    [Pg.112]    [Pg.247]    [Pg.798]    [Pg.839]    [Pg.281]    [Pg.203]    [Pg.358]    [Pg.106]    [Pg.41]    [Pg.60]    [Pg.64]    [Pg.125]    [Pg.242]    [Pg.242]    [Pg.269]    [Pg.285]    [Pg.348]    [Pg.384]    [Pg.444]    [Pg.458]    [Pg.128]    [Pg.50]    [Pg.60]    [Pg.444]    [Pg.574]   
See also in sourсe #XX -- [ Pg.890 ]




SEARCH



Presynaptic

© 2024 chempedia.info